Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.

Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A.

Ther Clin Risk Manag. 2014;10:9-15. doi: 10.2147/TCRM.S49428. Epub 2013 Dec 18.

2.

Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy.

Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL.

Ther Clin Risk Manag. 2012;8:377-84. doi: 10.2147/TCRM.S33674. Epub 2012 Sep 17.

3.

Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines.

Colombo GL, Di Matteo S, Antinori A, Medaglia M, Murachelli S, Rizzardini G.

Clinicoecon Outcomes Res. 2013 Oct 3;5:489-96. doi: 10.2147/CEOR.S48246. Review.

4.

Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.

Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P.

Clinicoecon Outcomes Res. 2011;3:197-205. doi: 10.2147/CEOR.S24130. Epub 2011 Oct 31.

6.

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A; AI266073 Study Group.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf.

PMID:
19357529
7.

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.

AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.

PMID:
21412057
8.
9.

Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.

Wilkins EL, Cohen CJ, Trottier B, Esser S, Smith DE, Haas B, Brinson C, Garner W, Chuck S, Thorpe D, De-Oertel S.

AIDS Care. 2016;28(3):401-8. doi: 10.1080/09540121.2015.1096890. Epub 2015 Oct 21.

PMID:
26489045
10.

The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART Regimens.

Jin S, Kim MH, Park JH, Jung HJ, Lee HJ, Kim SW, Lee JM, Kim S, Chang HH.

Infect Chemother. 2015 Dec;47(4):239-46. doi: 10.3947/ic.2015.47.4.239. Epub 2015 Dec 30.

11.

WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.

Omeje I, Okwundu CI.

Cochrane Database Syst Rev. 2012 May 16;(5):CD007276. doi: 10.1002/14651858.CD007276.pub3. Review.

PMID:
22592718
12.

WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.

Omeje I, Okwundu CI.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007276. doi: 10.1002/14651858.CD007276.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;(5):CD007276.

PMID:
22336829
13.

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.

van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, Rachlis A, Bloch M, Segal-Maurer S, Garner W, Porter D, Bosse M, Piontkowsky D, Chuck SK, De-Oertel S.

AIDS. 2016 Jan;30(2):251-9. doi: 10.1097/QAD.0000000000000911.

PMID:
26684822
14.

Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.

Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S, Stevens M, Rimsky L, Thorpe D, Bosse M, White K, Zhong L, DeMorin J, Chuck SK.

AIDS Patient Care STDS. 2014 Apr;28(4):168-75. doi: 10.1089/apc.2013.0310. Epub 2014 Mar 24.

15.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP; GS-236-0103 Study Team.

Lancet. 2012 Jun 30;379(9835):2429-38. doi: 10.1016/S0140-6736(12)60918-0.

PMID:
22748590
16.

Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.

Elzi L, Erb S, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M; Swiss HIV Cohort Study.

Arch Intern Med. 2012 Sep 24;172(17):1313-21. doi: 10.1001/archinternmed.2012.3216.

PMID:
22892835
17.

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.

Cohen C, Wohl D, Arribas JR, Henry K, Van Lunzen J, Bloch M, Towner W, Wilkins E, Ebrahimi R, Porter D, White K, Walker I, Chuck S, De-Oertel S, Fralich T.

AIDS. 2014 Apr 24;28(7):989-97. doi: 10.1097/QAD.0000000000000169.

PMID:
24508782
18.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.

PMID:
21182349
19.

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.

Pedrol E, Caro-Murillo AM, Castaño MA, Riera M, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Pulido F, Romero-Palacios A, Aguirrebengoa K, Vera F, Ferrer P, Blanco Ramos JR.

HIV Clin Trials. 2015 Jan-Feb;16(1):43-8. doi: 10.1179/1528433614Z.0000000001. Epub 2015 Jan 28.

PMID:
25777189
20.

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.

Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, Lazzarin A, Castagna A.

Medicine (Baltimore). 2016 May;95(22):e3780. doi: 10.1097/MD.0000000000003780.

Supplemental Content

Support Center